These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 25424771)

  • 21. [Relationship between HBeAg seroconversion with genotypes and HBV specific CTL in patients with chronic hepatitis B treated with Adefovir dipivoxil].
    Zhou YL; Wang XC; Wu YT; Tan YF; Zhao YP; Tang JM; Pan JQ; Yang ZX; Gu XB
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2011 Jun; 25(3):220-3. PubMed ID: 21977598
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Entecavir 1mg versus combined lamivudine/adefovir dipivoxil in chronic HBV Egyptian patients resistant to LAM monotherapy, non-randomised controlled study.
    Maklad S; Doss W; El Din SS; Hassan K; Zeid AA
    Arab J Gastroenterol; 2014 Mar; 15(1):1-5. PubMed ID: 24630505
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimal therapy of chronic hepatitis B: how do I treat HBeAg-positive patients?
    Vlachogiannakos J; Papatheodoridis GV
    Liver Int; 2015 Jan; 35 Suppl 1():100-6. PubMed ID: 25529094
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HBV DNA level as an important determinant of E antigen seroconversion of chronic hepatitis B during adefovir dipivoxil therapy.
    Tseng KC; Cheng PN; Wu IC; Chang CK; Chou AL; Liu WC; Chang TT
    Hepatogastroenterology; 2009; 56(91-92):813-8. PubMed ID: 19621708
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnosis and treatment of chronic hepatitis B: an update.
    Morgan M; Park W; Keeffe EB
    Minerva Gastroenterol Dietol; 2007 Mar; 53(1):25-41. PubMed ID: 17415343
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of chronic hepatitis B: Evolution over two decades.
    Yuen MF; Lai CL
    J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():138-43. PubMed ID: 21199525
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Two patterns of alanine aminotransferase increase to predict long-term viral response in chronic hepatitis B patients: virus- or host-induced?
    You H; Wu X; Ou X; Ma H; Wang Q; Liu T; Cong M; Wang P; Wang B; Jia J
    Antivir Ther; 2011; 16(3):299-307. PubMed ID: 21555812
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Successful withdrawal of antiviral treatment in kidney transplant recipients with chronic hepatitis B viral infection.
    Cho JH; Lim JH; Park GY; Kim JS; Kang YJ; Kwon O; Choi JY; Park SH; Kim YL; Kim HK; Huh S; Kim CD
    Transpl Infect Dis; 2014 Apr; 16(2):295-303. PubMed ID: 24628837
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low incidence of hepatitis B e antigen seroconversion in patients treated with oral nucleos(t)ides in routine practice.
    Lin B; Ha NB; Liu A; Trinh HN; Nguyen HA; Nguyen KK; Ahmed A; Keeffe EB; Garcia RT; Garcia G; Nguyen MH
    J Gastroenterol Hepatol; 2013 May; 28(5):855-60. PubMed ID: 23278507
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of HIV infection on response to tenofovir in patients with chronic hepatitis B.
    Plaza Z; Aguilera A; Mena A; Vispo E; Sierra-Enguita R; Tomé S; Pedreira J; Rodriguez C; Barreiro P; del Romero J; Soriano V; Poveda E
    AIDS; 2013 Sep; 27(14):2219-24. PubMed ID: 23669158
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The predictive value of ALT, HBeAg and HBV DNA levels at baseline and the degree of HBV suppression at week 12 adefovir dipivoxil treatment to the efficacy of it at week 52 in patients with HBeAg-positive chronic hepatitis B].
    Xie DY; Lin BL; Xu QH; Chen YM; Lu WL; Li JG; Gao ZL
    Zhonghua Gan Zang Bing Za Zhi; 2008 May; 16(5):341-4. PubMed ID: 18510844
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.
    Pellicelli AM; Barbaro G; Francavilla R; Romano M; Barbarini G; Mazzoni E; Mecenate F; Paffetti A; Barlattani A; Struglia C; Villani R; Nauri L; Nosotti L; Armignacco O; Ferri F; Camporiondo MP; Soccorsi F;
    Clin Ther; 2008 Feb; 30(2):317-23. PubMed ID: 18343270
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study.
    Moucari R; Korevaar A; Lada O; Martinot-Peignoux M; Boyer N; Mackiewicz V; Dauvergne A; Cardoso AC; Asselah T; Nicolas-Chanoine MH; Vidaud M; Valla D; Bedossa P; Marcellin P
    J Hepatol; 2009 Jun; 50(6):1084-92. PubMed ID: 19376603
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term outcomes after nucleos(t)ide analogue discontinuation in HBeAg-positive chronic hepatitis B patients.
    He D; Guo S; Zhu P; Tao S; Li M; Huang H; Wang J; Wang Y; Ding M
    Clin Microbiol Infect; 2014 Oct; 20(10):O687-93. PubMed ID: 25469947
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B.
    Reijnders JG; Perquin MJ; Zhang N; Hansen BE; Janssen HL
    Gastroenterology; 2010 Aug; 139(2):491-8. PubMed ID: 20381492
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized, placebo-controlled trial of tenofovir disoproxil fumarate in adolescents with chronic hepatitis B.
    Murray KF; Szenborn L; Wysocki J; Rossi S; Corsa AC; Dinh P; McHutchison J; Pang PS; Luminos LM; Pawlowska M; Mizerski J
    Hepatology; 2012 Dec; 56(6):2018-26. PubMed ID: 22544804
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy.
    Leung NW; Lai CL; Chang TT; Guan R; Lee CM; Ng KY; Lim SG; Wu PC; Dent JC; Edmundson S; Condreay LD; Chien RN;
    Hepatology; 2001 Jun; 33(6):1527-32. PubMed ID: 11391543
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years.
    Hadziyannis SJ; Tassopoulos NC; Heathcote EJ; Chang TT; Kitis G; Rizzetto M; Marcellin P; Lim SG; Goodman Z; Ma J; Brosgart CL; Borroto-Esoda K; Arterburn S; Chuck SL;
    Gastroenterology; 2006 Dec; 131(6):1743-51. PubMed ID: 17087951
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of the antiviral effects of different nucleos(t)ide analogues in chinese patients with chronic hepatitis B: a head-to-head study.
    Yu S; Zhou Q; Zhao XM; Yuan M; Wang CT; Cheng XG; Zhang ZH; Li X
    Saudi J Gastroenterol; 2014; 20(6):350-5. PubMed ID: 25434315
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine.
    Papatheodoridis GV; Dimou E; Dimakopoulos K; Manolakopoulos S; Rapti I; Kitis G; Tzourmakliotis D; Manesis E; Hadziyannis SJ
    Hepatology; 2005 Jul; 42(1):121-9. PubMed ID: 15962291
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.